Display options
Cite
Pan R, Wang J, Qi F, et al. Dosimetric comparison and observation of three-dimensional conformal radiotherapy for recurrent nasopharyngeal carcinoma. Oncol Lett. 2017;14(4):4741-4745doi: 10.3892/ol.2017.6732.
Pan, R., Wang, J., Qi, F., & Liu, R. (2017). Dosimetric comparison and observation of three-dimensional conformal radiotherapy for recurrent nasopharyngeal carcinoma. Oncology letters, 14(4), 4741-4745. https://doi.org/10.3892/ol.2017.6732
Pan, Rongqiang, et al. "Dosimetric comparison and observation of three-dimensional conformal radiotherapy for recurrent nasopharyngeal carcinoma." Oncology letters vol. 14,4 (2017): 4741-4745. doi: https://doi.org/10.3892/ol.2017.6732
Pan R, Wang J, Qi F, Liu R. Dosimetric comparison and observation of three-dimensional conformal radiotherapy for recurrent nasopharyngeal carcinoma. Oncol Lett. 2017 Oct;14(4):4741-4745. doi: 10.3892/ol.2017.6732. Epub 2017 Aug 08. PMID: 28943965; PMCID: PMC5594253.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2017 Oct;14(4):4741-4745. doi: 10.3892/ol.2017.6732. Epub 2017 Aug 08.

Dosimetric comparison and observation of three-dimensional conformal radiotherapy for recurrent nasopharyngeal carcinoma.

Oncology letters

Rongqiang Pan, Jingming Wang, Feng Qi, Ruizhen Liu

Affiliations

  1. Cancer Center, Nanchong Central Hospital, Nanchong, Sichuan 637000, P.R. China.
  2. Department of Ear, Nose and Throat, Gansu Provincial Maternity and Child Care Hospital, Lanzhou, Gansu 730050, P.R. China.
  3. Department of Radiotherapy, The First People's Hospital of Shangqiu, Shangqiu, Henan 476100, P.R. China.

PMID: 28943965 PMCID: PMC5594253 DOI: 10.3892/ol.2017.6732

Abstract

The aim of the study was to investigate the effect of three-dimensional conformal radiation therapy (3D-CRT) on nasopharyngeal carcinoma (NPC) and the incidence of complications. Between May 2010 and June 2012, 141 patients diagnosed with local recurrence of NPC due to cranial base lesions or cranial nerve symptoms, confirmed by pathology biopsy and/or by CT/MRI, were included in the present study. In accordance with the principle of randomized control, the patients were divided into three groups and treated with three different doses of 3D-CRT. The planned radiotherapy doses of 3D-CRT were 58/1.8-2 Gy, 62/1.8-2 Gy and 68/1.8-2 Gy, respectively. The survival rate, disease-free survival (DFS) rate and local control rate of the three groups of patients were compared as well as the adverse reactions observed after radiotherapy. The prognoses of NPC patients were analyzed by univariate and multivariate analyses. The follow-up rate of the study was 100%. The 5-year overall survival, DFS, and locoregional recurrence-free survival rates were: 43.2 vs. 64.53 vs. 75%, 29.13 vs. 42.82 vs. 39.7% and 30.76 vs. 44.19 vs. 45.4%, respectively. In addition, 62/1.8-2 Gy was similar in treatment effects to 68/1.8-2 Gy, but 68/1.8-2 Gy showed more adverse reactions than 62/1.8-2 Gy. Thus, 62/1.8-2 Gy can be used as a safe and effective dose for 3D-CRT treatment of NPC. Univariate and multivariate analyses showed that age may be the main prognostic factor of patients with NPC. In conclusion, 3D-CRT with a dose of 62/1.8-2 Gy is a safe, effective and tolerable treatment for NPC patients with good clinical value.

Keywords: 3D-CRT; local recurrence; nasopharyngeal carcinoma; re-irradiation

References

  1. Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):897-913 - PubMed
  2. Arch Otolaryngol Head Neck Surg. 2002 Mar;128(3):280-4 - PubMed
  3. Brain Res. 2016 Oct 1;1648(Pt A):387-93 - PubMed
  4. Oral Oncol. 2016 Sep;60:18-24 - PubMed
  5. Asia Pac J Clin Oncol. 2016 Dec;12 (4):460-467 - PubMed
  6. Radiother Oncol. 2000 Feb;54(2):135-42 - PubMed
  7. Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1331-8 - PubMed
  8. BMC Cancer. 2016 Aug 30;16:693 - PubMed
  9. Cancer Radiother. 2016 Sep;20 Suppl:S104-9 - PubMed
  10. Medicine (Baltimore). 2016 Jul;95(29):e4275 - PubMed
  11. Oral Oncol. 2015 Nov;51(11):1041-6 - PubMed
  12. Jpn J Clin Oncol. 2016 Oct;46(10 ):903-910 - PubMed
  13. Cancer Res Treat. 2017 Apr;49(2):518-525 - PubMed
  14. Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1095-113 - PubMed
  15. World J Surg. 2003 Jul;27(7):844-8 - PubMed
  16. Onco Targets Ther. 2016 Aug 18;9:5123-31 - PubMed
  17. Clin Oncol (R Coll Radiol). 2017 Jan;29(1):e47 - PubMed
  18. Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):761-9 - PubMed
  19. Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1254-64 - PubMed

Publication Types